Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK shares jumped on Thursday after the UK drugmaker reached a settlement of up to $2.2bn to resolve the vast majority of cases linked to its heartburn medicine Zantac.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

San Antonio attorney Mikal Watts is among a group of lawyers that negotiated a settlement of as much as $2.2 billion to resolve claims by about 80,000 people who allege a discontinued version of the ...

GSK (LSE: GSK) has settled 93% of Zantac (ranitidine) product liability cases in the USA, agreeing to pay up to $2.2 billion ...

Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GSK shares top the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...